Among the SIRT3 activators and inhibitors introduced above, no compounds targeting SIRT3 for cancer therapy have entered clinical trials, although honokiol has been used as a therapeutic agent for non-small cell lung cancer in China, but the relationship between honokiol and its activation of SIRT3 is ambiguous, and needs to be further explored 111. This evidence concerns the gene SIRT3 and non-small cell lung carcinoma.